El cáncer de próstata metastásico se presenta en el 20% de pacientes al momento del
diagnóstico de cáncer de próstata (1). Los sitios comunes de diseminación metastásica
locorregional son los ganglios linfáticos (99%) y huesos como pelvis, cadera y esqueleto axial
(84%); mientras que las localiz...
This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for olaparib. NHS organisations can get details on the Commercial Access and ...
This guideline covers the diagnosis and management of prostate cancer in secondary care,
including information on the best way to diagnose and identify different stages of the disease, and
how to manage adverse effects of treatment. It also includes recommendations on follow-up in
primary care for people...
